Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
65 hedge funds and large institutions have $88.5M invested in Avadel Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 15 closing their positions.
1.1% less ownership
Funds ownership: 51.4% → 50.31% (-1.1%)
13% less funds holding
Funds holding: 75 → 65 (-10)
30% less capital invested
Capital invested by funds: $126M → $88.5M (-$37.8M)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
55% less call options, than puts
Call options by funds: $160K | Put options by funds: $354K
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$7.37M |
| 2 |
Morgan Stanley
New York
|
+$1.59M |
| 3 |
BC
Broadfin Capital
New York
|
+$368K |
| 4 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$277K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.54M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.04M |
| 3 |
Millennium Management
New York
|
-$2.03M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.14M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1K | -206 | Closed |
|
|
CHP
77
Cable Hill Partners
Portland,
Oregon
| – | -$1K | -100 | Closed |
|
AVDL Hedge Fund Activity: Q3 2018 in Review
65 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2018, worth a combined $88.5M — down 30% from $126M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AVDL and 5 opened new positions — a net loss of 10 holders — while 23 trimmed existing stakes and 13 added.
The largest buyer was Brandes Investment Partners, adding an estimated $7.37M. The largest seller was Renaissance Technologies, cutting an estimated $2.54M.
- 65 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2018, down from 75 in Q2 2018.
- Funds reported $88.5M of Avadel Pharmaceuticals stock for Q3 2018, down 30% quarter-over-quarter.
- 5 funds opened new Avadel Pharmaceuticals positions in Q3 2018 and 15 closed out, a net change of -10 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2018 was Brandes Investment Partners, an estimated $7.37M added.
- The largest Avadel Pharmaceuticals seller in Q3 2018 was Renaissance Technologies, an estimated $2.54M sold.
Based on aggregated 13F filings for Q3 2018.